# Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

> **NCT03177460** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Testosterone Greater Than 150 ng/dL

## Interventions

- **BIOLOGICAL:** Daratumumab
- **DRUG:** FMS Inhibitor JNJ-40346527
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT03177460
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-07
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03177460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03177460, "Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03177460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*